These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 28624888

  • 1. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
    Božina N, Lalić Z, Nađ-Škegro S, Borić-Bilušić A, Božina T, Kaštelan Ž, Trkulja V.
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1129-1140. PubMed ID: 28624888
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F, Sanchez-Plumed J, Gentil MA, Kuypers DR, Brunet M, Ekberg H, Grinyó JM.
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [Abstract] [Full Text] [Related]

  • 4. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.
    Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y.
    Transplantation; 2006 Oct 27; 82(8):1074-84. PubMed ID: 17060857
    [Abstract] [Full Text] [Related]

  • 5. Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus.
    El-Sheikh AA, Koenderink JB, Wouterse AC, van den Broek PH, Verweij VG, Masereeuw R, Russel FG.
    Transl Res; 2014 Jul 27; 164(1):46-56. PubMed ID: 24486136
    [Abstract] [Full Text] [Related]

  • 6. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T.
    Eur J Clin Pharmacol; 2007 Dec 27; 63(12):1161-9. PubMed ID: 17906856
    [Abstract] [Full Text] [Related]

  • 7. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
    Lloberas N, Torras J, Cruzado JM, Andreu F, Oppenheimer F, Sánchez-Plumed J, Gentil MÁ, Brunet M, Ekberg H, Grinyó JM, Spanish Pharmacogenetic Symphony Substudy Group.
    Nephrol Dial Transplant; 2011 Nov 27; 26(11):3784-93. PubMed ID: 21427078
    [Abstract] [Full Text] [Related]

  • 8. Association of ABCC2 Haplotypes to Mycophenolic Acid Pharmacokinetics in Stable Kidney Transplant Recipients.
    Brazeau D, Meaney CJ, Consiglio JD, Wilding GE, Cooper LM, Venuto RC, Tornatore KM.
    J Clin Pharmacol; 2021 Dec 27; 61(12):1592-1605. PubMed ID: 34169529
    [Abstract] [Full Text] [Related]

  • 9. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
    Trkulja V, Lalić Z, Nađ-Škegro S, Lebo A, Granić P, Lovrić M, Pasini J, Božina N.
    Ther Drug Monit; 2014 Aug 27; 36(4):456-64. PubMed ID: 24518562
    [Abstract] [Full Text] [Related]

  • 10. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F.
    Clin Pharmacokinet; 2013 Sep 27; 52(9):751-62. PubMed ID: 23633119
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF, Yao X, Chen Y, Xie WQ, Shen-Tu JZ, Chen JH.
    Int J Clin Pract Suppl; 2014 Apr 27; (181):4-9. PubMed ID: 24673713
    [Abstract] [Full Text] [Related]

  • 12. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H, Höcker B, Fichtner A, van Damme-Lombaerts R, Friman S, Jaray J, Vondrak K, Sarvary E, Dello Strologo L, Oellerich M, von Ahsen N, Tönshoff B.
    Ther Drug Monit; 2017 Feb 27; 39(1):21-28. PubMed ID: 28030534
    [Abstract] [Full Text] [Related]

  • 13. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
    Geng F, Jiao Z, Dao YJ, Qiu XY, Ding JJ, Shi XJ, Li ZD, Zhong MK.
    Clin Chim Acta; 2012 Apr 11; 413(7-8):683-90. PubMed ID: 22227166
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.
    van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE.
    Ther Drug Monit; 2001 Apr 11; 23(2):119-28. PubMed ID: 11294511
    [Abstract] [Full Text] [Related]

  • 15. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
    Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S, Kagawa Y, Kawakami J.
    J Clin Pharmacol; 2009 Jun 11; 49(6):710-8. PubMed ID: 19451405
    [Abstract] [Full Text] [Related]

  • 16. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec 11; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 17. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.
    Musuamba FT, Mourad M, Haufroid V, Demeyer M, Capron A, Delattre IK, Delaruelle F, Wallemacq P, Verbeeck RK.
    J Clin Pharmacol; 2012 Dec 11; 52(12):1833-43. PubMed ID: 22207766
    [Abstract] [Full Text] [Related]

  • 18. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
    Cortinovis M, Gotti E, Pradini S, Gaspari F, Perico N.
    Transplantation; 2011 Sep 15; 92(5):550-6. PubMed ID: 21709602
    [Abstract] [Full Text] [Related]

  • 19. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.
    Park JM, Lake KD, Cibrik DM.
    Ther Drug Monit; 2008 Oct 15; 30(5):591-6. PubMed ID: 18708992
    [Abstract] [Full Text] [Related]

  • 20. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
    van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T.
    Clin Pharmacol Ther; 2009 Sep 15; 86(3):319-27. PubMed ID: 19494809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.